MedX Health Corp. Appoints Lesley Bourget as CFO

MedX Health Corp. has welcomed a new member to its executive team.

Lesley Bourget has been appointed chief financial officer (CFO). “On behalf of MedX’s Board of Directors and leadership team, I want to warmly welcome Lesley as she takes on the pivotal CFO role during a time of rapid growth for our company,” said Sylvain Desjeans, MedX president and CEO. “Lesley is an inspirational and visionary leader, with a long track record of supporting market growth through her extensive M&A negotiation and alliance-building experience for public pharmaceutical and health care companies. I look forward to working with Lesley to further harness MedX’s growth opportunities ahead.”

Bourget’s appointment will further support MedX’s global commercialization strategy, as the company seeks to build on the momentum of current commercial and product distribution pilots underway across North America and Europe, with additional pilots anticipated in the coming months.
 
With more than 30 years’ experience in healthcare, pharmaceutical and CPG industries, Bourget has successfully led product portfolio optimization efforts, negotiating large-scale acquisitions, and conceiving and implementing mergers in the R&D space. She most recently served as CFO of Aspen Pharmacare Canada, where she was instrumental in achieving company-record profit levels, and optimizing inventory and wholesaler processes.

Bourget is a certified management accountant (CPA, CMA) and is qualified in international financial reporting through an IFRS Certification (CMA). 
 
“I was drawn to MedX due to its mission of saving lives and its technology’s unique ability to make teledermatology accessible for patients around the world. Strengthening virtual health-care services has never been more important than it is now, amid a global pandemic. I feel privileged to join the MedX team to help fulfill its growth potential and improve patient outcomes,” Bourget said.
 
Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care—both patient screening and assessment—eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, MedX’s telemedicine platform allows healthcare practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. MedX’s DermSecure Screening Platform then transmits these high-resolution images safely and securely for virtual dermatological assessment by a certified dermatologist within just 72 hours, compared to a wait time of up to 90 days for traditional dermatological assessment.
 
MedX, headquartered in Ontario, Canada, is a medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also embedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485-certified facility. SIAMETRICS, SIMSYS, and MoleMate are approved by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne.